Cure8 trial brief
This registry-based study compares early control of inflammation on conventional therapy versus escalating to advanced treatments in newly diagnosed ulcerative colitis, using CRP and fecal calprotectin to define inadequate control. Its results could influence decisions about timing of treatment escalation.
Clinicians treating newly diagnosed UC, researchers in IBD treatment sequencing and biomarkers, and patients newly diagnosed with UC interested in escalation strategies.
This is a non-interventional, observational study using the Lothian IBD registry (planned enrollment ~4000). It defines cohorts by inflammation control status in the first 6–24 months after diagnosis and will compare outcomes for patients remaining on conventional therapies versus those who escalate treatment.
Primary measures include proportions achieving early control of inflammation and differences in inadequate control at 24 months. The study uses routinely collected biomarker data (CRP and fecal calprotectin) rather than assigning treatments, so it reflects real-world practice.
As an observational registry analysis, it can show associations but cannot by itself prove that switching earlier causes better outcomes.
As an observational, non-interventional registry study, the design can identify associations but cannot establish causation. The protocol focuses on biomarker-defined inflammation (CRP and fecal calprotectin) in routine care and compares outcomes up to 24 months post-diagnosis.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
A dietary multi-mineral supplement is being tested in a Phase 2 trial to see if it can improve symptoms, influence inflammation biomarkers, and help induce or maintain remission in people with ulcerative colitis.
A microbiome-targeted, food-grade supplement could offer a non-immunosuppressive option for people with mild-to-moderate ulcerative colitis who remain inflamed or want to delay immunosuppressive/biologic therapy. The...
If donor ethnicity or specific microbial/metabolite signatures influence FMT success, results could help identify optimal donors or develop targeted microbiota-based treatments for ulcerative colitis.
